Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
Takeaways: Lilly now offers Canadian pediatric endocrinologists a once‑weekly injectable that addresses both glycemic control and weight – two core drivers of aggressiv...
